Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guci Qutong Gao (骨刺祛痛膏) is a Traditional Chinese Medicine (TCM) topical plaster developed and marketed by Jiangsu Gaitianli Pharmaceutical, a subsidiary of the Xiuzheng Pharmaceutical Group. It is indicated for the treatment of pain and inflammation associated with bone spurs (osteophytes), osteoarthritis, cervical spondylosis, and lumbar spondylosis. The formulation is a complex mixture of herbal ingredients, typically including processed *Radix Aconiti Kusnezoffii* (制草乌), processed *Radix Aconiti* (制川乌), processed *Semen Strychni* (制马钱子), Frankincense (*Ru Xiang*), and Myrrh (*Mo Yao*). These components work synergistically to promote local blood circulation, dispel cold, and provide potent analgesic effects. The plaster is applied transdermally to the affected area, allowing for the localized absorption of active alkaloids and terpenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guci qutong gao.